Decoding Your Pathology and Surgical Reports

After surgery for ependymoma, you will receive two critical documents: the operative report from the surgeon and the pathology report from the laboratory. Together, these documents form the roadmap for your future treatment ^[1]. Understanding the technical language in these reports allows you to ask more precise questions and ensure you are receiving care based on the most current medical standards.

The Operative Report: Evaluating the Surgery

The surgeon’s primary goal in ependymoma treatment is to remove as much of the tumor as safely possible ^[2]. The operative report will describe the Extent of Resection (EOR) using two key terms:

• Gross Total Resection (GTR): This means the surgeon was able to remove all visible tumor during the procedure ^[3]. GTR is the “cornerstone” of treatment because it is the single most important factor in reducing the risk of the tumor coming back and improving long-term survival ^[4][5].
• Subtotal Resection (STR): This means some of the tumor was left behind, usually because it was too close to critical nerves or blood vessels to be safely removed ^[6]. If an STR occurs, your team may discuss a “second-look” surgery (an additional operation usually planned within days or weeks after reviewing the post-op MRI) to remove the remaining pieces ^[7][6].

Note: A GTR is typically confirmed by a “clean” MRI scan performed within 48 to 72 hours after surgery ^[8].

The Pathology Report: Decoding the Biology

While the surgeon looks at the tumor’s size, the pathologist looks at its biology. According to the 2021 WHO guidelines, a modern report must provide an Integrated Diagnosis—a summary that combines what the cells look like (histology) with their genetic “fingerprint” (molecular data) ^[1][9].

The Importance of Molecular Testing

Traditional microscope viewing is no longer enough to properly type an ependymoma ^[10]. Your report should ideally include results from:

• DNA Methylation Profiling: This is the “gold standard” test that identifies which of the nine molecular subgroups the tumor belongs to (e.g., PFA vs. PFB) ^[11].
• Immunohistochemistry (IHC): A test that uses antibodies to find specific proteins. For example, a loss of the H3K27me3 protein helps identify the more aggressive PFA subgroup ^[12].
• Fusion Testing: Tests to see if genes have fused together, such as the ZFTA or YAP1 fusions ^[13].

Your “Completeness Checklist”

When you review your reports, ensure these four essential data points are clearly stated. If any are missing, you may need to request an addendum (an official update to the report) or a second opinion ^[1].

1. Anatomic Location: Is it Supratentorial, Posterior Fossa, or Spinal? ^[8]
2. Extent of Resection (EOR): Is it listed as GTR or STR? ^[3]
3. WHO Grade: Is it Grade 2 or Grade 3? (Note: Grade 1 is now very rare for most ependymomas, though a specific, slower-growing tumor called a Subependymoma remains Grade 1) ^[14].
4. Molecular Subtype: Does it list a specific subgroup (like ZFTA-fused or PFA)? ^[11]

Proactive Steps

If your report only says “Ependymoma, Not Otherwise Specified (NOS),” it means the molecular testing was either not done or was unsuccessful ^[8]. Because molecular subtype is critical for deciding whether you need radiation or specialized clinical trials, you should feel empowered to ask your doctor: “Has this tissue been sent for DNA methylation profiling to confirm the molecular subgroup?” ^[11][15].

Once you understand your pathology report, you are well-prepared to discuss the Standard of Care: Surgery, Radiation, and Trials.